We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
101
ALX Oncology
ALXO
$275M
– –
-117,817
Closed -$133K
ATXS
102
DELISTED
Astria Therapeutics
ATXS
– –
-4,000
Closed -$52.4K
BLTE
103
Belite Bio
BLTE
$7B
– –
-9,161
Closed -$1.47M
CDTX
104
DELISTED
Cidara Therapeutics
CDTX
– –
-3,026
Closed -$668K
DYN icon
105
Dyne Therapeutics
DYN
$4.91B
– –
-70,180
Closed -$1.37M
ELDN icon
106
Eledon Pharmaceuticals
ELDN
$296M
– –
-6,000
Closed -$9.06K
ENTA icon
107
Enanta Pharmaceuticals
ENTA
$400M
– –
-2,270
Closed -$35.8K
EXEL icon
108
Exelixis
EXEL
$12.6B
– –
-68,569
Closed -$3.01M
FOLD
109
DELISTED
Amicus Therapeutics
FOLD
– –
-82,500
Closed -$1.17M
GBIO
110
DELISTED
Generation Bio
GBIO
– –
-5,376
Closed -$30.5K
IMUX icon
111
Immunic
IMUX
$216M
– –
-15,522
Closed -$82.8K
NAMS icon
112
NewAmsterdam Pharma
NAMS
$3.32B
– –
-4,000
Closed -$140K
NRIX icon
113
Nurix Therapeutics
NRIX
$2.76B
– –
-20,000
Closed -$379K
PLRX icon
114
Pliant Therapeutics
PLRX
$67.5M
– –
-276,500
Closed -$337K
PRAX icon
115
Praxis Precision Medicines
PRAX
$10.7B
– –
-2,700
Closed -$796K
QURE icon
116
uniQure
QURE
$3.12B
– –
-8,742
Closed -$209K
RGC icon
117
Regencell Bioscience
RGC
$2.59B
– –
-4,400
Closed -$92.4K
RLMD icon
118
Relmada Therapeutics
RLMD
$501M
– –
-154,109
Closed -$744K
TERN
119
DELISTED
Terns Pharmaceuticals
TERN
– –
-130,413
Closed -$5.27M
VIR icon
120
Vir Biotechnology
VIR
$1.55B
– –
-200
Closed -$1.21K
VKTX icon
121
Viking Therapeutics
VKTX
$3.91B
– –
-6,000
Closed -$211K
VRDN icon
122
Viridian Therapeutics
VRDN
$2.55B
– –
-14,654
Closed -$456K
VTGN icon
123
VistaGen Therapeutics
VTGN
$11.7M
– –
-62,701
Closed -$41.5K
ZURA icon
124
Zura Bio
ZURA
$550M
– –
-166,500
Closed -$872K
ZYME icon
125
Zymeworks
ZYME
$1.79B
– –
-20,600
Closed -$542K
2 3 4
5
6

Similar funds

SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
FNWM
Financial Network Wealth Management Draper, Utah $316M AUM
MJFG
Mars Jewett Financial Group Bellevue, Washington $316M AUM
KC
KHIS Custodian Dallas, Texas $316M AUM
EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
WA
Waterford Advisors Orchard Park, New York $315M AUM 15.21% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.